Posttranslational Modifications of Smurfs: Emerging Regulation in Cancer

Longtao Yang1, Wenwen Zhou1 and Hui Lin2*

1 Second Clinical Medical School, Nanchang University, Nanchang, China, 2 Department of Pathophysiology, School of Basic Medical Sciences, Nanchang University, Nanchang, China

Smad ubiquitination regulatory factors (Smurfs) belong to the Nedd4 subfamily of HECT-type E3 ubiquitin ligases. Under normal situations, Smurfs are exactly managed by upstream regulators, and thereby strictly control tumor biological processes, including cell growth, differentiation, apoptosis, polarization, epithelial mesenchymal transition (EMT), and invasion. Disruption of Smurf activity has been implicated in cancer progression, and Smurf activity is controlled by a series of posttranslational modifications (PTMs), including phosphorylation, ubiquitination, neddylation, sumoylation, and methylation. The effect and function of Smurfs depend on PTMs and regulate biological processes. Specifically, these modifications regulate the functional expression of Smurfs by affecting protein degradation and protein interactions. In this review, we summarize the complexity and diversity of Smurf PTMs from biochemical and biological perspectives and highlight the understanding of their roles in cancer.

Keywords: Smurfs, posttranslational modification (PTM), cancer, phosphorylation, ubiquitination

INTRODUCTION

Smurfs regulate effectors in a host of signaling cascades (e.g., TGF-β, BMP, RAS, Wnt) (1). The function of Smurfs is to mediate mono- or poly-ubiquitination of substrates, which modulates the stability, abundance, and positioning of the protein (1). In fact, protein ubiquitination is a dynamic and multifaceted posttranslational modification that involves the control of nearly all physiological activities in eukaryotic cells (2). The diversity and complexity of regulatory mechanisms also require that Smurfs’ recognition and ubiquitination of substrates must be a highly specific and adjustable process. As is known to all, the specific amino acid sequence and spatial structure in biological element determine the interaction between proteins, which is closely related to their functions (3). Smurfs are no exception, containing multiple domains that match their functions. The molecular weight of Smurfs is measured by kilodalton (kD), which is a unit used for counting the algebraic sum of the atomic weights of all atoms in the molecule (4). Human Smurf1 contains an N-terminal C2 domain (14–99 kD) for phospholipids and Ca²⁺ binding (5), two WW domains (234–267 kD; 280–313 kD) primarily for interaction with PPXY or LPXY motifs and phospho-serine/threonine residues of substrates (6), as well as a C-terminal HECT domain (394–731 kD) for transferring ubiquitin from the catalytically active site Cys699 to substrates (7) (Figure 1). Human Smurf2 has one additional WW domain (297–330 kD) based on Smurf1, and its catalytically active site is Cys716 (8) (Figure 2).
Early on, it was found that Smurfs could guide the direction of tumor biological processes through TGF-β signaling. As E3 ligases, Smurfs are involved in the ubiquitination and degradation of TGF-β receptors, and the ubiquitination process involves crosstalk between Smurfs and Smad proteins (9). The Smurf1/2-Smad7 complex not only triggers proteasomal degradation of TβRI via ubiquitination but also blocks Smad3 complex formation by mono-ubiquitinating Smad3, both of which result in downregulation of the TGF-β signaling pathway (10, 11). TGF-β signaling is intimately correlated with cancer. However, its effects on cancers are not homogeneous; instead, it drives tumors toward two completely opposite outcomes at different stages. During the early stage of cancer, the TGF-β cascade inhibits cell proliferation and induces apoptosis (12); however, in advanced cancer, disordered TGF-β pathway signaling reverses that inhibition (13).

Numerous studies have found that in addition to relying on the TGF-β pathway, Smurfs also modulate tumor cell activities in a TGF-β cascade-independent manner, which broadens the diversity of Smurfs’ substrates. Due to their substrate diversity and specificity, Smurfs play a negative or positive role in tumor development. Specifically, as a tumor promoter, Smurf1/2, which is remarkably highly expressed in tumor cells, leads to poor prognosis. For example, Smurf1 boosts cell invasion by degrading tumor suppressors [e.g., Ras homolog gene family member A (RhoA), hPEM-2, DAB2 interacting protein (DAB2IP), Kindlin-2] and altering cellular localization of substrates [e.g., tumor necrosis factor receptor-associated factor 4 (TRAF4)] (14–18), and it inhibits p53/DNA damage-mediated apoptosis by degrading corresponding factors (e.g., ING2, RhoB, KLF2) and stabilizing MDM2 (19–22). Stabilization of Mad2 and Nedd9, mediated by Smurf2, facilitates the cell cycle (23, 24). However, Smurfs, when acting as tumor suppressors, inhibit tumor development. At the protein level, Smurf1 suppresses tumor progression via inhibition of cell proliferation, survival, and metastasis by degrading TRIB2, MCAM, and SRF5, as well as by nonproteolytically regulating AXIN1 (25–28). Tumorigenesis is repressed by Smurf2 through its degradation of Id1 via ubiquitination and its facilitation of autophagosome-mediated lysosomal turnover of LaminA/progerin (29, 30). At the transcriptional levels, Smurf2 mediates degradation of transcriptional factors (e.g., KLF5, YY1), which blocks cell proliferation (31, 32), and decreases susceptibility to various cancers by maintaining genomic stability (33, 34). Furthermore, some of Smurfs’ special substrates [e.g., Skp1-cullin-1-F-box protein (SCF) ubiquitin ligase complex, ring
finger protein 20 (RNF20) have a wholly opposite role in tumor progression in different cell types and cellular contexts, which further broadens the complexity of Smurfs’ regulation of biological functions (33, 35–37).

In short, due to the dual role of Smurfs in tumors, along with the diversity and complexity of their downstream regulatory mechanisms, Smurfs seem to act as decisive regulators among signaling pathways, but they do not act alone in cancer cells. To a certain extent, Smurfs themselves are largely affected by numerous upstream factors. With respect to protein levels, some adaptors (e.g., Smad6/7) interact with Smurf1/2, enhancing its ubiquitin ligase activity toward proteins, while several regulatory elements (e.g., PTPN3) block the binding of Smurfs to their substrates, hindering substrate degradation (1). In addition to the effects of noncovalent binding, in recent years a host of studies have investigated important posttranslational modifications of Smurfs, including phosphorylation, ubiquitination, neddylation, sumoylation, and methylation, and the significance of PTMs has become increasingly prominent in cancers (Table 1). PTMs regulate Smurfs in a highly specific manner, providing unique potential targets with high specificity and accuracy. In this context, summarizing upstream regulatory factors of Smurfs and the effects of Smurf modifications on their substrates is significant for an in-depth analysis of Smurfs’ biological functions and tumor-targeted therapies.

**PHOSPHORYLATION**

Protein phosphorylation is the most comprehensively studied PTM in cancers. It is a diverse process in which the phosphate group, delivered by energy carrier like Adenosine Triphosphate (ATP), covalently binds to amino acid residue (e.g., serine, tyrosine, threonine) (56) under the ordered participation of a series of molecules, such as soluble and membrane-bound extracellular chemical molecules, membrane receptors, second messengers, protein kinases (57, 58). Like other proteins, in tumor cells, Smurfs can be phosphorylated by common protein kinases [e.g., protein kinase A (PKA), PKB], and the functions of phosphorylation can be distinctive in specific tumor types. At times, phosphorylation can completely reverse the original effect of Smurfs on tumors, such as PKA inhibiting lung cancer cell growth by decreasing Smurf1 activity (38). However, at other times, phosphorylation functions as a signaling pathway to enhance positive/negative impacts of Smurfs on cancers without changing Smurfs’ original direction of action. For example, phosphorylation of Smurf1 on Thr145 is not important for DAB2IP binding, Smurf1-mediated degradation of DAB2IP, or modulation of Smad1, but it does cause Smurf1 abundance and structural stability, which further increases the degradation of DAB2IP, resulting in tumor progression (16). Phosphorylation of Smurfs by protein kinases has a plethora of...
implications in biological processes, including governing Smurf ubiquitin ligase activity, stability, and relative affinities for proteins, as well as mediating Smurfs’ unconventional ubiquitination of substrates, even inducing autoubiquitination and degradation of Smurfs themselves. Under diverse circumstances, phosphorylation events are closely associated with cellular processes, such as cell growth, apoptosis, proliferation, migration, and EMT (Figures 1 and 2).

**Smurf1 Phosphorylation**

Phosphorylation of Smurf1 plays a dual role in tumor development. In different tumor types, it either boosts tumor cell progression through triggering ubiquitination and degradation of tumor suppressors [e.g., Type Iγ phosphatidylinositol phosphate kinase (PIPKIγ), DAB2IP] or induces apoptosis by promoting the abundance of corresponding factors (e.g., Nur77, RhoA) (Figure 1).

In some cancers, Smurf1 is phosphorylated at specific threonine residues by cAMP/PKA, which modulates Smurf1 ubiquitin ligase activity or mediates its unconventional ubiquitination of substrates. In lung cancer cells, PKA-Smurfl-PIPKIγ signal transduction plays a positive role in lung cancer cell growth and in vivo tumorigenesis (38). Phosphorylation of threonine residue T306 by PKA inhibits Smurf1 ubiquitin ligase activity, which abolishes Smurf1-mediated ubiquitination-dependent proteasomal degradation of PIPKIγ. PIPKIγ is reportedly highly expressed in lung cancer cells and phosphorylates and activates β-Catenin, a downstream regulator in the Wnt/Wingless signaling pathway, resulting in increased β-Catenin transcriptional activity that stimulates tumorigenic phenotypes and cell growth (40, 59). Stimulated by the chemotherapy drug cisplatin, in HeLa cells, PKA drives Smurf1 to unconventionally ubiquitinate the orphan receptor Nur77 at the K6 or K27 linkage by phosphorylation of Smurf1, which also occurs at Thr306 (39). Conventional ubiquitination refers to the modification that leads to the degradation of the substrate proteins in the proteasome (60). For example, ubiquitination
mediated by Smurf1 at Lys255 drives proteasome-dependent degradation of PIPKIγ (38). However, noncanonical ubiquitination, serving as non-degradative signaling to modulate target protein stability and localization (61), elevates protein levels of Nur77, causing subsequent Nur77 translocation into the mitochondria to induce cancer cell apoptosis (39). Interestingly, in cancer cells not treated with cisplatin, c-Jun N-terminal kinase (JNK) downregulates Nur77 (39). Nonetheless, K6 or K27 ubiquitination precludes Nur77 from degradation (39). Furthermore, phosphorylation of Smurf1 by PKA at Thr306 enhances the affinity of Smurf1 for RhoA instead of cell polarity protein Par6, accelerating degradation of RhoA via ubiquitination and leading to neuronal polarization (20, 62).

Akt (also called PKB), whose modulation is frequently disordered in various cancers, is a serine/threonine kinase (63). In colorectal cancer cells, phosphorylation by Akt1/2 on Smurf1 Thr145 augments Smurf1 protein stability to control DAB2IP abundance, which contributes to increased ubiquitination and degradation of tumor suppressor DAB2IP, dampening DAB2IP’s inhibitory effect on tumor cells (16). Without degradation by Smurf1, DAB2IP negatively regulates downstream pathways, but Smurf1 enhances Ras-MAPK and NF-kB oncogenic pathways by targeting DAB2IP, which bolsters tumor cell proliferation, survival, and migration (16). Interestingly, in ovarian cancer, Smurf1 also upregulates the AKT/Skp2 pathway, which further encourages cell invasiveness and EMT (64).

Other protein kinases, such as checkpoint kinase (Chk1) and Interleukin-1 Receptor Associated Kinase 2 (IRAK2), can reduce protein levels of phosphorylated Smurf1 at Thr145, Thr161, and Thr682 compared to its basic expression in cancers. In response to ultraviolet light or methyl methane-sulphonate (MMS), in HCT116 cells, phosphorylation of Smurf1 by Chk1 at Thr145, Thr161, and Thr682 motivates autoubiquitination-mediated Smurf1 degradation, leading to suppression of Smurf1-mediated degradation of RhoB. This results in RhoB accumulation and thus DNA damage-induced apoptosis (20). Due to RhoB promoting apoptosis in various cancer cells, this finding illustrates that in some cancers, Smurf1 might act as an oncoprotein to degrade RhoB and facilitate tumorigenesis (20). Meanwhile, in colorectal cancer cells, autoubiquitination and degradation of Smurf1, which is induced by ER stress stimulated IRAK2-mediated phosphorylation also at Thr145, Thr161, and Thr682, results in an altered cascade of ER effectors to inhibit cell growth and promote apoptosis (41). Therefore, upregulation of Smurf1 is associated with poor prognosis in colorectal cancer; however, the detailed mechanisms need to be further investigated (41).

**Smurf2 Phosphorylation**

Among many signal cascades, TGF-β signaling is one link between Smurf2 and tumor cellular responses. It has been well established that TGF-β signaling boosts tumor cell cycle in advanced cancers (13). Smurf2 downregulates TGF-β signaling by ubiquitination degrading its primary downstream components, such as Smad2/3 and TβR (10). However, this Smurf2 function can be reversed by phosphorylation events, leading to the promotion of TGF-β signaling-mediated tumor progression (65).

HGF/c-MET signaling is positively involved in tumor development, especially in terms of cell invasion and metastasis (66). In bladder cancer cells, tyrosine kinases c-SRC and LCK, which are driven by HGF/c-MET signaling, phosphorylate Smurf2 at Tyr314/434. Smurf2 binding capacity to Smad7 is subsequently obstructed, and intramolecular C2-HECT interaction of Smurf2 is enhanced, both of which inhibit Smurf2 ubiquitin ligase activity. This action suppresses Smurf2 activity toward TβR and results in enhanced typical TGF-β signaling and TGF-β-mediated EMT, as well as cell invasion (42). This substantiates the hypothesis that HGF/c-MET needs a functional TGF-β signaling pathway for induction of tumor cell invasion and metastasis, which is realized through indirect downregulation of Smurf2 (42).

**UBIQUITINATION**

Protein ubiquitination is a common PTM defined as the covalent attachment of ubiquitin to amino acid residues of proteins, such as Lys, which is catalyzed by a defined set of enzymes (67). The ubiquitination process is achieved by the ordered action of three enzymes. Consuming energy provided by ATP, ubiquitin-activating enzyme (E1) interacts with and activates ubiquitin and then transfers ubiquitin to ubiquitin-conjugating enzyme (E2). Finally, the ubiquitin ligase (E3), in tandem with the E2 enzyme, recognizes and ubiquitinates the target protein (68). Ubiquitination events primarily trigger proteasomal degradation of proteins via Lys48-linked ubiquitination (61). Furthermore, ubiquitination can alter intracellular protein localization and biological activity, except for Lys48-linked ubiquitination (61). In tumor cells, ubiquitination of Smurfs mediated by regulatory proteins (e.g., Smurf2, CKIP-1, TRAF4, TRB3) aggravates the degradation of Smurfs through the proteasome pathway, leading to elevated protein levels of their substrates (e.g., RhoA, p53, Smad3) and subsequent tumor biological functions, such as cell growth, migration, and invasion, are regulated (Figure 3).

**Smurf1 Ubiquitination**

An intermediate thioester formed by Cys699 within the C-terminus of the Smurf1 HECT domain and Gly76 of ubiquitin is pivotal to Smurf1 ubiquitin ligase activity and autoubiquitination (10, 69, 70). The thioester transfers ubiquitin to lysine residues of ubiquitin and activates ubiquitin and then transfers ubiquitin to ubiquitin-conjugating enzyme (E2). Finally, the ubiquitin ligase (E3), in tandem with the E2 enzyme, recognizes and ubiquitinates the target protein (68). Ubiquitination events primarily trigger proteasomal degradation of proteins via Lys48-linked ubiquitination (61). Furthermore, ubiquitination can alter intracellular protein localization and biological activity, except for Lys48-linked ubiquitination (61). In tumor cells, ubiquitination of Smurfs mediated by regulatory proteins (e.g., Smurf2, CKIP-1, TRAF4, TRB3) aggravates the degradation of Smurfs through the proteasome pathway, leading to elevated protein levels of their substrates (e.g., RhoA, p53, Smad3) and subsequent tumor biological functions, such as cell growth, migration, and invasion, are regulated (Figure 3).

**Smurf1 Ubiquitination**

An intermediate thioester formed by Cys699 within the C-terminus of the Smurf1 HECT domain and Gly76 of ubiquitin is pivotal to Smurf1 ubiquitin ligase activity and autoubiquitination (10, 69, 70). The thioester transfers ubiquitin to lysine residues of ubiquitin and activates ubiquitin and then transfers ubiquitin to ubiquitin-conjugating enzyme (E2). Finally, the ubiquitin ligase (E3), in tandem with the E2 enzyme, recognizes and ubiquitinates the target protein (68). Ubiquitination events primarily trigger proteasomal degradation of proteins via Lys48-linked ubiquitination (61). Furthermore, ubiquitination can alter intracellular protein localization and biological activity, except for Lys48-linked ubiquitination (61). In tumor cells, ubiquitination of Smurfs mediated by regulatory proteins (e.g., Smurf2, CKIP-1, TRAF4, TRB3) aggravates the degradation of Smurfs through the proteasome pathway, leading to elevated protein levels of their substrates (e.g., RhoA, p53, Smad3) and subsequent tumor biological functions, such as cell growth, migration, and invasion, are regulated (Figure 3).
TGF-β-independent mechanism that leads to cell migration (43). Smurf1 is unable to directly ubiquitinate Smurf2, but it indirectly promotes ubiquitination of Smurf2 via mono-ubiquitinating and stabilizing TRAF4. TRAF4 facilitates poly-ubiquitination of Smurf2, leading to its degradation (18, 43). In another study, in breast cancer cells ubiquitination of Smurf1 could be reversed by the deubiquitinating enzyme USP9X through Smurf1 WW domain binding, which improved Smurf1’s stability (70). Then, Smurf1 disrupted the stability of growth-inhibitory protein RhoA by ubiquitinating and degrading RhoA, thereby promoting breast cancer cell mobility and plasticity (70). Therefore, we could conclude that Smurf1 facilitates breast cancer cell migration in a RhoA-dependent manner. In breast cancer cells, the mechanism of Smurf1 ubiquitination mediated by Smurf2, as well as Smurf1-induced mechanisms independent of TGF-β signaling, need to be further studied (43).

As a tumor suppressor, Casein kinase-2 interacting protein-1 (CKIP-1) represses Smurf1 synthesis and is responsible for autoubiquitination and degradation of Smurf1 in colon cancer cells. Then, due to low protein levels of Smurf1, the Smurf1-mediated degradation of tumor suppressor p53 is repressed, and upregulated p53 suppresses colon cancer cell growth and migration (44). The study found that Smurf1 was aberrantly expressed in colon cancer tissues, and upregulation of Smurf1 was associated with downregulation of CKIP-1 (44). However, the data showed that the protein level of Smurf1 was decreased in a concentration-dependent manner after being transfected with CKIP-1 in HCT116 cells (44). Interestingly, it has been demonstrated that a highly conserved sequence within the Smurf1 WW linker (L271NxVxCxEL279) mediates the interaction between CKIP-1 and Smurf1. Smurf2 fails to be ubiquitinated by CKIP-1 owing to a lack of this sequence (72). Surprisingly, ubiquitination induced by CKIP-1 in different types of cells, can lead to a distinct fate of Smurf1. In osteoblasts, CKIP-1 is responsible for the robust ubiquitin ligase activity of Smurf1 (72, 73). Therefore, unveiling the mechanisms of how CKIP-1 stimulating autoubiquitination of Smurf1 and thereby affecting its activity in tumor cells is a subject worthy of further researching.
F-box and leucine rich repeat protein 15 (Fbxl15) and F-box protein 3 (Fbxo3) stimulate the poly-ubiquitination and proteasomal degradation of Smurf1 by forming the SCF ubiquitin ligase complex (45, 46, 74). Through Smurf1 HECT domain binding, ubiquitination events induced by Fbxl15 at Smurf1 Lys355 and Lys357 downregulate Smurf1, which impedes Smurf1-mediated degradation of p-Smad1/5 and enhances BMP signaling (45). After Smurf1’s ubiquitination by Fbxl15, the P97-NPL4 complex formed by P97 and coenzyme nucleoprotein localization site 4 (NPL4) specifically binds to the Smurf1 PEST motif (350–373 kD) in which K355 and K357 are located and accelerates the transfer of ubiquitinated Smurf1 to the proteasome for degradation, ultimately facilitating ALK4-induced TGF-β signaling (45). This finding indicates that the P97-NPL4 complex plays a key role in Fbxl15-mediated ubiquitination and degradation of Smurf1 (46, 75). Like Fbxl15, Fbxo3 connects to Smurf1 and binds to the WW or HECT domain on Smurf1, mediating Smurf1 ubiquitination and degradation. Downregulation of Smurf1 leads to elevated protein levels of its substrates Smad1/5 and promotes BMP-2-induced BMP signaling responsiveness (46).

There are regulatory proteins (e.g., CKIP-1, Fbxo3, Fbxl15, Smurf2) that mediate ubiquitination of Smurf1. However, some factors inhibit this process. Embryonic mesoderm induction experiments found that binding of VprBP to the Smurf1-Smad7 complex decreased Smurf1 poly-ubiquitination at Lys667 (47). This action enhances Smurf1 stability, driving the Smurf1-Smad7 complex to facilitate ubiquitination and degradation of TβRI. It results in reduced TGF-β-induced phosphorylation of Smad2 and then attenuated expression of downstream target gene, thereby inhibiting embryonic mesoderm induction (47).

**Smurf2 Ubiquitination**

TGF-β signaling is a bridge between the ubiquitination of Smurf2 and tumor cell activities (Figure 2). All of these ubiquitination events, which induce Smurf2 degradation, have a positive impact on the progression of TGF-β signaling.

Previously, we discussed that in breast cancer cells, Smurf1 boosts cell migration in a TGF-β-independent manner, which can be reversed by Smurf2 (43). However, ubiquitination of Smurf2 driven by TRAF4 in breast cancer causes Smurf2 degradation, leading to suppression of Smurf2-induced degradation of TβRI and resulting in the promotion of TGF-β cascade-induced cell migration, EMT, and invasion (18). Furthermore, deubiquitinating enzyme USP15, recruited by TRAF4, not only stabilizes TβRI but also removes ubiquitin from Smurf2 Lys734, resulting in repression of Smurf2 activity (18, 76). Deubiquitinas preplay a crucial role in ubiquitin-directed signaling by catalyzing the deubiquitination of substrate proteins (76). USP15 deubiquitirates Smurf2 at Lys734, a residue required for Smurf2 transthiolation and catalytic activity. Therefore, Smurf2 ubiquitin ligase activity toward TβRI is opposed by Lys734 deubiquitination, resulting in activation of TGF-β signaling (77). As mentioned above, we postulate that the negative effect of Smurf1 on TGF-β signaling is completely offset by the downregulation (in protein levels and ubiquitin ligase activity) of Smurf2, with the final result being enhanced TGF-β signaling that promotes breast cancer progression.

In TGF-β signaling, there is a feedback mechanism that governs protein levels of Smurf2 (48). In the absence of the TβR target, Smurf2 enhances its catalytic activity with respect to autoubiquitination with the help of Smad7 anchoring UbcH7 to the Smurf2 HECT domain, which leads to Smurf2 degradation and controls its resting state levels (48). However, in the presence of TβR, the binding of Smad7 with Smurf2 relieves the autoinhibition of Smurf2 by abrogating its intramolecular interaction, and this binding enhances Smurf2 ubiquitin ligase activity to inactivate TGF-β signaling (48). Furthermore, Smad7-induced autoubiquitination of Smurf2 might be another molecular mechanism of Smurf2 autoinhibition. Intramolecular interaction inhibits Smurf2 ubiquitin ligase activity, while, the Smad7-induced enhances its autoubiquitination and degradation, both of which involve the alteration of Smurf2 catalytic activity (48). It has also been indicated that three phosphorylation sites (T144 within the Smurf2 WW1 domain, T168 and T170 in C2-WW1 linker) might govern autoinhibition of Smurf2 mediated by intramolecular interactions (78). However, whether these sites regulate Smad7-Smurf2 autoinhibition remains unknown and it will broaden the horizon of regulatory mechanism of Smurf2 autoinhibition.

Tribbles homolog 3 (TRB3) and Tetratricopeptide Repeat Domain 3 (TTC3) directly ubiquitinate Smurf2, thereby mediating Smurf2 degradation in a proteasome-dependent manner. TRB3, which belongs to the pseudokinase family, is overexpressed in numerous human cell lines (49). In HepG2 cells, ubiquitination of Smurf2 by TRB3 protects Smad3 from Smurf1-mediated ubiquitination and degradation, leading to an increase in the stabilization of Smad3. Thus, the TGF-β1-Smad3 signaling pathway is augmented and activates cell migration and invasion (49). TTC3 can function as a ubiquitin E3 ligase, and its involvement in cancer cells is not well recognized (79). Poly-ubiquitination of Smurf2 by TTC3 at Lys48 relieves Smurf2-mediated degradation of Smad2/3. High protein levels of Smad2/3 lead to enhanced TGF-β signaling, which subsequently propels bronchial epithelial cell EMT (50).

**NEDDYLLATION**

Similar to ubiquitination, protein neddylation is a highly ordered process (80–82). Nedd8, a highly conserved ubiquitin-like molecule containing 81 amino acid residues with 80% homology to ubiquitin (83), is conjugated to an E1 enzyme (dimer NAE composed of APPBP1 and UBA3), which then transfers Nedd8 onto an E2 enzyme (e.g., UBC12). The E3 enzyme (e.g., Rbx1, MDM2, SCFFBXO11), cooperating with the E2 enzyme, delivers Nedd8 to lysine residues on the protein. Consequently, neddylation not only controls protein steady-state levels, but also changes the localization and function of modified proteins (83–88). Neddylation events mediated by UBC12 and noncovalent binding regions within Smurfs’ HECT domain enhance Smurf ubiquitin ligase activity toward substrates and/or themselves and regulate Smurf stability (Figure 3). During neddylation, both Smurf1 and Smurf2 exert functional changes.
Nedd8 ligase activity to catalyze autonneddylation of themselves, but the regulatory mechanisms by which Nedd8 binds to Smurfs are still unclear (52, 53). Neddylated Smurfs modulate cellular processes in tumors, as shown in colorectal cancer, including cell proliferation, growth, invasion, and migration, by degrading tumor suppressors (e.g., RhoA), ultimately promoting cancer progression (Figures 1 and 2).

**Smurf1 Neddylation**

Neddylation events driven by different factors result in activation or destabilization of Smurf1. However, effects of the noncovalent binding region on Smurf1 are complicated and multifaceted, since this region is tightly correlated with both Smurf1 neddylation and ubiquitination and may help identify novel functions of neddylation events (51), which will be discussed below.

A highly conserved Nedd8 binding sequence (L(X7)R(X5)F(X)ALQ) is discovered in the noncovalent binding region and plays a positive role in Smurf1 autonneddylation, autoubiquitination, and its ubiquitin ligase activity toward substrates, such as Smad1/5 and RhoA (51). Neddylation mediated by noncovalent binding region within the Smurf1 HECT domain destabilizes Smurf1 expression levels. When Leu, Arg, Phe, Leu, and Glu residues in the sequence were mutated to Ala (the 10A mutation), noncovalent binding of Smurf1 with Nedd8 was abolished, which partially hindered Smurf1 autonneddylation and maintained Smurf1 stability (51). In addition, Smurf1-10A selectively blocked the formation of the thioester intermediate between Smurf1 and ubiquitin, resulting in partial inhibition of Smurf1 ubiquitin ligase activity toward Smad1/5 and RhoA substrates. Upregulation of Smad1/5 and RhoA contributed to enhanced BMP signaling pathway and prevention of cell migration, respectively. Although the noncovalent binding region in Smurf1 takes a role in the promotion of cell migration, whether there is a link between neddylation of Smurf1 and cancer cell migration is unknown (51). Moreover, owing to the repression of the ubiquitin thioester intermediate formation, Smurf1-10A also suppressed Smurf1 autoubiquitination. However, 10A did not affect binding of Nedd8 to Smurf1 Cys426, both of which formed a Nedd8 thioester intermediate. Cys426 facilitates the formation of Nedd8 thioester intermediate. Cys426 facilitates the transfer of Nedd8 for covalent conjugation, leading to Smurf1 autonneddylation (52). Then, through the recruitment of a ubiquitin-conjugating enzyme (E2), neddylated Smurf1 induces ubiquitination and degradation of RhoA, enhancing cell migration. Besides, Smad4/5 is also degraded via Smurf1 ubiquitinating (52). In this regard, the capability of Smurf1 activated by neddylation to facilitate physiological processes of colorectal cancer cells maybe also in a manner independent of TGF-β signaling. The ultimate result of this neddylation event is the acceleration of colorectal cancer cell proliferation, migration, invasion, and growth (52).

**Smurf2 Neddylation**

In addition to Smurf1, Smurf2 is also subject to regulation by neddylation (53). Smurf2 interacts with Nedd8 and UBC12 to form a thioester intermediate and exerts its Nedd8 ligase activity to catalyze its autonneddylation. Neddylation enhances Smurf2 autoubiquitination and ubiquitin ligase activity toward substrates, which leads to ubiquitin-proteasomal degradation of itself and substrates respectively, by recruiting the ubiquitin-conjugating enzyme (E2) (53). Neddlylation sites of Smurf2 include Lys19-24, a cluster in the N-terminal region of the Smurf2 HECT domain. Other regions within the HECT domain also have neddylation sites besides the N-terminal region. However, the covalent binding regions of Smurf2 are smaller than that of Smurf1 (52, 53). After being neddylated, Smurf2 translocates into nucleus, besides, it was previously reported that Smurf2 could maintain genome stability and decrease susceptibility to tumorigenesis by controlling RNF20 in the nucleus (33, 53). Therefore, it further noted that neddylation events might trigger Smurf2 to target RNF20 for degradation, consequently modulating chromatin conformation and tumorigenesis (33, 53). But which cancer cellular processes are affected by neddylation events is still unclear. Neddylation sites and substrates of neddylated Smurf2 in cancer cells need to be further investigated (53).

**OTHER POSTTRANSLATIONAL MODIFICATIONS**

**Sumoylation**

Protein sumoylation refers to the covalent binding of small ubiquitin-like modifiers (SUMOs) with lysine residues on proteins and occurs under the combined action of multiple enzymes, including SUMO E1 activating enzyme, SUMO-conjugating enzyme (E2), and SUMO E3 ligase (89). Like Nedd8, SUMO is also a ubiquitin-like molecule, and at this point, the sumoylation process is understood as similar to that of ubiquitination (90). After being sumoylated, protein stability, cellular distribution, activity, and interactions can be governed (91–94). In mammary epithelial cell-derived acini, sumoylation of Smurf2 by the SUMO E3 ligase (PIAS3) at Lys26 and Lys369 enhances Smurf2 stability and ubiquitin ligase activity (54). However, the sumoylation process is reversible, and SUMO
molecules that covalently bind with Smurf2 can be removed by the SUMO isopeptidases SENP1/2 (54). Sumoylated Smurf2 promotes the degradation of TβRI via ubiquitination, restraining TGF-β signaling-mediated EMT (54). EMT is a fundamental biological process for epithelial malignant tumor cells to acquire the ability of migration and invasion (95). Thus, to further explore the effects of Smurf2 sumoylation on the progression of human breast cancer, these researchers identified that this PIAS3-sumoylated Smurf2 axis also functions as a suppressor of TGF-β signaling in human breast cancer cell-derived organoids, impairing TGF-β-induced cell invasion and growth (96). Without doubt, this novel axis lays the foundation for the development of new ideas in the treatment of breast cancer.

**Methylation**

Protein methylation is well characterized and involves covalent conjugation between a methyl group and arginine or lysine residues located in protein side chains and in the N- or C-terminus (97). During this process, methyl groups are diverted by methyltransferase from methyl donors, such as S-adenosyl methionine (SAM), to substrates (98, 99). Methylation alters the properties of a protein with respect to activity, stability, positioning, and affinity for other proteins (97, 100, 101). Interestingly, the methylation process varies from one kind of residue to another. Under catalysis of arginine methyltransferase, arginine can be mono- or asymmetrically symmetrically dimethylated. Catalyzed by lysine methyltransferase, lysine can be mono-, di- or trimethylated (97, 100). For Smurf2, protein arginine methyltransferase 1 (PRMT1), which handles more than 90% of type 1 protein arginine methyltransferase activity in cells, is in charge of mono- or dimethylation of internal Arg in Smurf2. Methylation of Smurf2 mediated by PRMT1 at Arg232, Arg234, Arg237, and Arg239 contributes to enhanced TGF-β signaling-mediated reporter activity (55). Methylation does not change Smurf2 ubiquitin ligase activity, as the affinity of Smurf2 for substrates in the TGF-β signaling pathway, such as Smads and TβR, was not altered in response to methylation (55). Moreover, the cellular localization of methylated Smurf2 was also not changed relative to that of the methylation-defective mutant Smurf2 (55). Therefore, methylation events might reduce Smurf2 protein stability at the protein levels, ultimately modulating the TGF-β signaling pathway (55). Although Smurf1 shares almost 80% sequence identity with Smurf2, PRMT1 is incapable of methylating Smurf1 (55).

**CONCLUSIONS AND PERSPECTIVES**

Smurfs play a crucial role in numerous tumor biological functions. It is now evident that whether Smurfs promote or inhibit tumor development depends largely on tumor types and on the PTMs that they undergo, such as phosphorylation, ubiquitination, neddylation, sumoylation, and methylation (Figures 1 and 2). Because PTMs determine the functions of Smurfs and thus the fate of Smurf substrates, the control of Smurfs in tumor-related cellular processes is strictly and specifically modulated by upstream regulators. These upstream effects are widely applied in controlling Smurf1/2 ubiquitin ligase activity, stability (in protein levels), and interaction with other proteins, and they even mediate Smurfs’ unconventional ubiquitination of substrates (Figure 3). Indeed, upstream regulators vary from one kind of tumor cell to another, and it is cancer types that determine which PTMs occur (Tables 1, 2). Accordingly, modification events alter Smurf management of downstream cascades, ultimately leading to promotion or inhibition of tumor progression. A typical example includes phosphorylation of Smurf1 by PKA, which inhibits Smurf1 activity and thus leads to the inhibition of Smurf1-mediated ubiquitination-dependent proteasomal degradation of PI3Kγ, resulting in lung cancer cell growth (38). Furthermore, we suspect that the occurrence of PTMs on Smurfs partially relies on sequence differences between Smurf1 and Smurf2. Although Smurf1 and Smurf2 have high structural homology, their sequence differences determine whether PTMs occur. For example, CKIP-1 mediates ubiquitination of Smurf1 rather than Smurf2 because Smurf1 contains a L271NxVxCxEL279 sequence (44). Surprisingly, to date, we also discover that there is no in vivo evidence of such modifications occurring in normal and cancer patient-derived tissues. Therefore, we think that in different cancer types, due to low protein levels of Smurf1/2 and/or deficiency of external stimulus of upstream factors, it makes it difficult to detect vivo Smurf modifications (39, 49). Meantime, modification events in vivo could be affected by cytokines released from other types of tissues (102). Nonetheless, vitro experiments of cancer cells can also reflect modification events occurring in normal and cancer tissues to a great extent (96). But we still believe that it is important to detect in vivo modification events, which will provide a more comprehensive molecular basis for following cancer treatment. Based on the molecular mechanisms of PTMs in Smurfs, it is of great necessity to apply

**TABLE 2 | The role of Smurfs in various cancer types.**

| Smurfs | Cancer type | Downstream protein | Promotion of biological processes | Inhibition of biological processes | Reference |
|--------|-------------|-------------------|----------------------------------|---------------------------------|-----------|
| Smurf1 | lung cancer | PIPKγ             | /                                | growth, tumorigenesis           | (38)      |
|        | colorectal cancer | DAB2IP           | /                                | /                               | (16)      |
|        | colorectal cancer | ER effectors     | /                                | /                               | (9)       |
|        | colorectal cancer | RhoB             | /                                | /                               | (20)      |
|        | colon cancer    | p53              | /                                | /                               | (42)      |
|        | breast cancer   | RhoA             | /                                | /                               | (49)      |
|        | bladder cancer  | TβRI             | /                                | /                               | (18)      |
|        | hepatoma        | Smad3            | /                                | /                               | (18)      |
|        | breast cancer   | TβRI             | /                                | /                               | (18)      |

Frontiers in Oncology | www.frontiersin.org 9  February 2021 | Volume 10 | Article 6106639
targeted therapeutic molecules and drugs that target Smurfs or upstream regulatory factors to stimulate or block Smurf PTMs in order to treat cancers.

Like other E3 ubiquitin ligases such as Mdm2, Smurf1/2 is a determinant in the genesis and/or development of some cancer types (Table 2), and leads to poorer survival of patients. It could be promising drug targets for cancer treatment (41). As highly conserved structures of Smurf1/2 domains, it is possible to design synthetic inhibitors such as peptides to disrupt Smurf1/2-substrate interaction (44, 103). At present, molecules targeting Smurfs are constantly appearing. Estrogen (ER), a growth factor, is significant for cell proliferation (104). Studies have shown that estrogen stimulates ERα to form a ternary complex with Smad2 and Smurf1, which induces simultaneous proteolysis of Smad2 and Smurf1 via ubiquitination, inhibiting the TGF-β signaling pathway (105). Researchers have also discovered drugs that activate/inactivate upstream regulators of Smurfs. It has been reported that ipatasertib and paclitaxel blocked PI3K/AKT-induced phosphorylation and activation of Smurf1 and prevented Smurf1-mediated ubiquitination and degradation of DAB2IP. As a result, DAB2IP inhibits triple-negative breast cancer cell proliferation and migration (106). Moreover, in ovarian cancer, Smurf1, acting as an oncogene, facilitates cell invasiveness and EMT, partially via reversibly activating AKT/Skp2 signaling, and treatment with ipatasertib and paclitaxel might also exhibit efficacy in ovarian cancer (64). Cisplatin activated cAMP/PAK-mediated phosphorylation of Smurf1, leading to accumulation of Nur77 and resulting in cancer cell apoptosis (39). In another disease such as heterotopic ossification, metformin-activated AMPK induces phosphorylation and activation of Smurf1. Then, Smurf1 prevents osteoblast differentiation by degrading Runx2 (107, 108). Although metformin has been widely utilized in the treatment and prevention of cancers, so far, no relevant studies have found that it has effects on cancers through activating the phosphorylation of Smurfs (109). Owing to the limitations of these studies, clinical trials that target the molecular mechanisms of Smurf PTMs require further investigation. In this regard, significant topics, which need to be settled in future studies, include further understanding of the molecular mechanisms of Smurf PTMs and cross talk between PTMs, such as neddylation and ubiquitination. Moreover, although some PTMs (e.g., phosphorylation) are relatively well documented, the importance of others (e.g., neddylation, methylation, sumoylation) is less understood. Together, how Smurf posttranslational modifications occur, how they are terminated, and how they affect downstream pathways and cellular processes thereby determining the fate of tumors will be the focus of Smurf research for many years to come. Furthermore, breakthroughs in the molecular mechanisms of Smurf PTMs may provide new therapeutic targets for drug development.

**AUTHOR CONTRIBUTIONS**

HL, LY, and WZ conceptualized and designed the review. LY, WZ, and HL drafted the article. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the National Natural Science Foundation of China (grant number: 31900852 to HL), Natural Science Foundation of Jiangxi Province (grant numbers: 2018BAB215012 and 2019ACB21026 to HL), and Development Fund Project from Jiangxi Medical College of Nanchang University (grant number: PY201801). HL was supported by scholarship from the China Scholar Council (201906825051).

**REFERENCES**

1. Fu L, Cui C-P, Zhang X, Zhang L. The functions and regulation of Smurfs in cancers. Semin Cancer Biol (2019) 67(Pt 2):102–16. doi: 10.1016/j.semcancer.2019.12.023
2. Zheng N, Shabek N. Ubiquitin Ligases: Structure, Function, and Regulation. Annu Rev Biochem (2017) 86:129–57. doi: 10.1146/annurev-biochem-060815-014922
3. Osadchy M, Kolodny R. Maps of protein structure space reveal a fundamental relationship between protein structure and function. Proc Natl Acad Sci U.S.A. (2011) 108:12301–6. doi: 10.1073/pnas.1102727108
4. Young G, Hundt N, Cole D, Fineberg A, Andreka J, Tyler A, et al. Quantitative mass imaging of single biological macromolecules. Science (2018) 360:423–7. doi: 10.1126/science.aar5893
5. Ingham RJ, Gish G, Pawson T. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene (2004) 23:2071–8. doi: 10.1038/sj.onc.1207436
6. Scheffner M, Kumar S. Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects. Biochim Biophys Acta (2014) 1843:61–74. doi: 10.1016/j.bbamcr.2013.03.024
7. Cao Y, Zhang L. A Smurf1 tale: function and regulation of an ubiquitin ligase in multiple cellular networks. Cell Mol Life Sci (2013) 70:2305–17. doi: 10.1007/s00018-012-1170-7
8. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem (2000) 275:36818–22. doi: 10.1074/jbc.C000580200
9. Izzi L, Attisano L. Regulation of the TGFβ signalling pathway by ubiquitin-mediated degradation. Oncogene (2004) 23:2071–8. doi: 10.1038/sj.onc.1207436
10. Koganti P, Levy-Cohen G, Blank M. Smurfs in Protein Homeostasis, Signaling, and Cancer. Front Oncol (2018) 8:295. doi: 10.3389/fonc.2018.00295
11. Tang L-Y, Yamashita M, Cousseins NP, Tang Y, Wang X, Li C, et al. Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3. EMBO J (2011) 30:4777–89. doi: 10.1038/ emboj.2011.393
12. Zhang Y, Alexander PB, Wang X-F. TGF-β Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb Perspect Biol (2017) 9: a022145. doi: 10.1101/cshperspect.a022145
13. Cobal S, Dijke P. Targeting TGF-β Signaling in Cancer. Trends Cancer (2017) 3:56–71. doi: 10.1016/j.trecan.2016.11.008
14. Wang H-R, Zhang Y, Ondzamar B, Ogunjimi AA, Alexandrova E, Thomsen GH, et al. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science (2003) 302:1775–9. doi: 10.1126/ science.1090772
15. Yamaguchi K, Ohara O, Ando A, Nagase T. Smurf1 directly targets hPEM-2, a GEF for Cdc42, via a novel combination of protein interaction modules in the ubiquitin-proteasome pathway. Biochem Biophys Res Commun (2008) 389:405–13. doi: 10.1515/BC.2008.036
24. Moore FE, Osmundson EC, Koblinski J, Pugacheva E, Golemis EA, Ray D, et al. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Mol Cell (2013) 51:559–72. doi: 10.1016/j.molcel.2013.07.014

27. Chen Y, Huang Q, Liu W, Zhu Q, Cui C-P, Xu L, et al. Mutually exclusive activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression. Nat Commun (2019) 10:4349. doi: 10.1038/s41467-019-12241-2

29. Kong Y, Cui H, Zhang H. Smurf2-mediated ubiquitination and degradation. Front Cell Biol (2016) 7:26057–69. doi: 10.3389/fncel.2016.026057

31. Du JX, Hagos EG, Nandan MO, Bialkowska AB, Yu B, Yang VW. The emerging roles of F-box proteins in pancreatic tumorigenesis. Semin Cancer Biol (2016) 36:88–94. doi: 10.1016/j.semcancer.2015.09.004

34. Yu L, Dong L, Wang Y, Liu L, Long H, Li H, et al. Reversible regulation of Id1 ubiquitinates during senescence. Aging Cell (2011) 10:92. doi: 10.1038/srep00746

35. Wang H, Maitra A, Wang H. The WW-HECT protein Smurf2 interacts with the Docking Protein NEDD9/HEF1 for Aurora A activation. J Cell Biol (2010) 1843:2005–13. doi: 10.1016/j.jcb.2010.02.013

36. Lau AW, Fukushima H, Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 17:2197–212. doi: 10.2741/4045

37. Sethi G, Shannamuk MG, Arfuso F, Kumar AP. Role of RNF20 in cancer development and progression - a comprehensive review. Biosci Rep (2018) 38:BSR20171287. doi: 10.1042/BSR20171287

38. Li H, Xiao N, Wang Y, Wang R, Chen Y, Pan W, et al. Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKII. Oncogene (2017) 36:5686–80. doi: 10.1038/onc.2017.166

39. Lin H, Lin Q, Liu M, Lin Y, Wang X, Chen H, et al. PKA/Smurf1 signaling-mediated stabilization of Nur77 is required for anticancer drug cisplatin-induced apoptosis. Oncogene (2014) 33:1629–39. doi: 10.1038/onc.2013.116

40. Cheng P, Lu H, Shelly M, Gao H, Poo M. Phosphorylation of E3 ligase Smurf1 switches its substrate preference in support of axon development. Neuron (2011) 69:231–43. doi: 10.1016/j.neuron.2010.12.021

41. Liu J, Chen Y, Huang Q, Liu W, Ji X, Hu F, et al. IAK2 counterbalances oncogenic Smurf1 in colon cancer cells by dictating ER stress. Cell Signal (2018) 48:69–80. doi: 10.1016/j.cellsig.2018.05.001

42. Sim WJ, Iyengar PV, Lama D, Li SKL, Ng HC, Haviñ-Shapira I, et al. c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression. Nat Commun (2019) 10:4349. doi: 10.1038/s41467-019-12241-2

43. Fujikazu E, Inoue Y, Komiya S, Horiguchi K, Goto K, Saitoh M, et al. Smurf2 induces Ubiquitin-dependent Degradation of Smurf1 to Prevent Migration of Breast Cancer Cells. J Biol Chem (2008) 283:35660–7. doi: 10.1074/jbc.M710462000

44. Nie J, Liu L, Xing G, Zhang M, Wei R, Guo M, et al. CKIP-1 acts as a colonic tumor suppressor by repressing oncogenic Smurf1 synthesis and promoting Smurf1 autodegradation. Oncogene (2016) 35:8000. doi: 10.1038/onc.2016.28

45. Cui H, He S, Xing G, Liu K, Wang X, Guo M, et al. SCDFFBXL5 regulates BMP signalling by directing the degradation of HECT-type ubiquitin ligase Smurf1. EMBO J (2011) 30:2675–89. doi: 10.1038/emoj.2011.155

46. Li D, Xie P, Zhao F, Shu J, Li L, Zhan Y, Zhang L. F-box protein Fbx3 targets Smurf1 ubiquitin ligase for ubiquitination and degradation. Biochem Biophys Res Commun (2015) 458:941–5. doi: 10.1016/j.jbc.2015.02.089

47. Li Y, Cui X, Xie F, Kieblbasa S, Mei H, van Dinther M, et al. VprBP mitigates TGF-β and Activin signaling by promoting Smurf1-mediated type I receptor degradation. J Mol Cell Biol (2019) 12(2):138–51. doi: 10.1093/jmcb/jmj057

48. Ogunjimi AA, Briant DJ, Pece-Barbara N, Le Roy C, Di Guglielmo GM, Kavask P, et al. Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. Mol Cell (2005) 19:297–308. doi: 10.1016/j.jolc.2005.06.028

49. Hua F, Mu R, Liu J, Xue J, Wang Z, Lin H, et al. TRB3 interacts with SMAD3 promoting tumor cell migration and invasion. J Cell Sci (2011) 124:3235–46. doi: 10.1242/jcs.082875

50. Kim J-H, Ham S, Lee Y, Suh GB, Lee Y-S. TCC3 contributes to TGF-β-induced epithelial-mesenchymal transition and myofibroblast differentiation, potentially through SMURF2 ubiquitination and degradation. Cell Death Dis (2019) 10:92. doi: 10.1038/s41419-019-1308-8

51. He S, Cao Y, Xie P, Dong G, Zhang L. The Ned88 Non-covalent Binding Region in the Smurf HECT Domain is Critical to its Ubiquitin Ligase Function. Sci Rep (2017) 7:41364. doi: 10.1038/srep41364

52. Xie P, Zhang M, He S, Lu K, Chen Y, Xing G, et al. The covalent modifier Ned88 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis. Nat Commun (2014) 5:3733. doi: 10.1038/ncomms4733

53. Shu J, Liu C, Wei R, Xie P, He S, Zhang L. Ned88 targets ubiquitin ligase Smurf2 for neddylation and promote its degradation. Biochem Biophys Res Commun (2016) 474:51–6. doi: 10.1016/j.bbrc.2016.04.058

54. Chandhoke AS, Karve K, Dadakhujaev S, Netherton S, Deng L, Bonni S. The ubiquitin ligase Smurf2 suppresses TGF-β-induced epithelial–mesenchymal transition in a somoylation-regulated manner. Cell Death Differ (2016) 23:876–88. doi: 10.1038/cdd.2015.152

55. Cha B, Park Y, Hwang BN, Kim S, Jo E. Protein Arginine Methyltransferase 1 Methyllates Smurf2. Mol Cells (2015) 38:723–8. doi: 10.14338/ molc.2015.0113

56. Humphrey SJ, James DE, Mann M. Protein Phosphorylation: A Major Switch Mechanism for Metabolic Regulation. Trends Endocrinol Metab (2015) 26:676–87. doi: 10.1016/j.tem.2015.09.013
Yang et al. Posttranslational Modifications of Smurfs in Cancer

57. Cohen P. The regulation of protein function by multisite phosphorylation—a 25 year update. *Trends Biochem Sci* (2000) 25:596–601. doi: 10.1016/s0968- 0004(00)01712-6
58. Pawson T, Scott JD. Protein phosphorylation in signaling – 50 years and counting. *Trends Biochem Sci* (2005) 30:286–90. doi: 10.1016/j.tibs.2005. 04.013
59. Schramp M, Thapa N, Heck J, Anderson R. PIPKI
60. Hapak SM, Rothlin CV, Ghosh S. PAR3-PAR6-atypical PKC polarity loop.
61. Fan X, Wang Y, Fan J, Chen R, Chen Y, Cui C-P, et al. VCP/p97 increases BMP regulation of Smurf2 in TGF-β signaling. *Front Mol Biosci* (2015) 2:106. doi: 10.3389/fmolb.2015.00128
62. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligase Smurf1 for activation by CKIP-1. *FASEB J* (2008) 22:2976–8. doi: 10.1096/fj.07-083333
63. Schramp M, Thapa N, Heck J, Anderson R. PIPKI
64. Fan X, Wang Y, Fan J, Chen R. Deletion of SMURF 1 represses ovarian cancer progression mediated by the nuclear amine oxidase homolog LSD1. *Cell Mol Life Sci* (2018) 75:3136–25. doi: 10.1007/s00018-018-2828-6
65. Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. *Expert Opin Investig Drugs* (2019) 28:977–88. doi: 10.1097/1fl.0000000000000256
66. Fan X, Wang Y, Fan J, Chen R. Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop. *J Cell Biochem* (2019) 120:10643–51. doi: 10.1002/jcb.28354
67. Iyengar PV, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, et al. USP15 and Smurf2 complex proteins in neuronal polarization. *Cell Mol Life Sci* (2018) 75:2735–61. doi: 10.1007/s00018-018-2826-8
68. Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. *Expert Opin Investig Drugs* (2019) 28:977–88. doi: 10.1097/1fl.0000000000000256
69. Nie J, Wu M, Wang J, Xing G, He F, Zhang L. REGgamma proteasome-dependent transcriptional activity downstream of growth factor receptor signaling. *Cell Biol Int* (2013) 37:1014–25. doi: 10.1002/cbin.20118
70. Zheng N, Wang Z, Wei W. Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins. *FASEB J* (2004) 18:1551–6. doi: 10.1096/fj.03-030772
71. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. *Cancer Cell* (2008) 14:10–21. doi: 10.1016/j.ccr.2008.06.001
72. Liu K, Xin X, Weng T, Xi S, Li L, Xing G, et al. Targeting WW domains linker of HECT ubiquitin ligase Smurfl for activation by CKIP-1. *Nat Cell Biol* (2008) 10:1994–1002. doi: 10.1038/ncc7690
73. Wan L, Zou W, Gao D, Inuzuka H, Fukushima H, Berg AH, et al. Cdh1 neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. *Cell Mol Life Sci* (2017) 74:128. doi: 10.1007/s00018-017-0128-0
74. Zhou K, Zhou W, Cai Q, Cheng J, Cai R, Xing R. SUMOylation of KLF4 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. *Oncotarget* (2016) 7:8497–56. doi: 10.18632/oncotarget.7923
75. Johnson ES. Protein modification by SUMO. *Annu Rev Biochem* (2004) 73:355–82. doi: 10.1146/annurev.biochem.73.011303.074118
76. CAPASSO O, Pekar O, Horowitz M. SUMOylation of EHD3 Modulates Tubulation of the Endocytic Recycling Compartment. *PloS One* (2015) 10: e0134053. doi: 10.1371/journal.pone.0134053
77. Hu M-M, Yang Q, Xie X-Q, Liao C-Y, Lin H, Liu T-T, et al. Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus. *Immunity* (2016) 45:555–69. doi: 10.1016/j.immuni.2016.08.014
78. Wang K, Zhou W, Cai Q, Cheng J, Cai R, Xing R. SUMOylation of KLFL4 interacts with the ER and regulates SMURF2. *Cell Cycle* (2017) 16:374–81. doi: 10.1080/15384101.2016.1269045
79. Masoumi KC, Marfany G, Yu Y, Massoumi R. Putative role of Smurf2 in TGF-β signaling. *Pharmacol Res* (2016) 110:1–10. doi: 10.1016/j.phrs.2016.02.005
80. Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. *Expert Opin Investig Drugs* (2019) 28:977–88. doi: 10.1097/1fl.0000000000000256
81. Lu K, Xin X, Weng T, Xi S, Li L, Xing G, et al. Targeting WW domains linker of HECT ubiquitin ligase Smurfl for activation by CKIP-1. *Nat Cell Biol* (2008) 10:1994–1002. doi: 10.1038/ncc7690
82. Choo YS, Zhang Z. Detection of protein ubiquitination. *Proteomics: A bioinformatic resource dedicated to physiological protein phosphorylation. Proteomics* (2004) 4:1551–61. doi: 10.1002/pmic.200300772
83. Suizu F, Hiramukii Y, Okumura F, Matsuda M, Okumura AJ, Hirata N, et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. *Dev Cell* (2009) 17:800–10. doi: 10.1016/j.devcel.2009. 09.007
84. Hao Y, Zhang Z, Wei W. Ubiquitination-mediated degradation of cell-cycle-related proteins by F-box proteins. *Int J Biochem Cell Biol* (2016) 73:99–110. doi: 10.1016/j.biocel.2016.02.005
85. Li H, Cui Y, Wei J, Liu C, Chen Y, Cui C-P, et al. VCP/p97 increases BMP signaling by accelerating ubiquitin ligase Smurf1 degradation. *FASEB J* (2019) 33:2928–43. doi: 10.1096/fj.20180173R
86. Chou C-K, Chang Y-T, Korinek M, Chen Y-T, Yang Y-T, Leu S, et al. The Regulations of Deubiquitinase USP15 and Its Pathophysiological Mechanisms in Diseases. *Int J Mol Sci* (2017) 18(3):15. doi: 10.3390/ijms18030483
87. Iyengar PV, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, et al. USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. *Sci Rep* (2015) 5:14733. doi: 10.1038/srep14733
88. Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B. PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. *Proteomics* (2004) 4:1551–61. doi: 10.1002/pmic.200300772
89. Suizu F, Hiramukii Y, Okumura F, Matsuda M, Okumura AJ, Hirata N, et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. *Dev Cell* (2009) 17:800–10. doi: 10.1016/j.devcel.2009. 09.007
105. Ito I, Hanyu A, Wayama M, Geto N, Katsuno Y, Kawasaki S, et al. Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem (2010) 285:14747–55. doi: 10.1074/jbc.M109.093039

106. Kim S-B, Dent R, Im S-A, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol (2017) 18:1360–72. doi: 10.1016/S1470-2045(17)30450-3

107. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, Saxon L, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone (2010) 47:309–19. doi: 10.1016/j.bone.2010.04.596

108. Shimazu J, Wei J, Karsenty G. Smurf1 Inhibits Osteoblast Differentiation, Bone Formation, and Glucose Homeostasis through Serine 148. Cell Rep (2016) 15:27–35. doi: 10.1016/j.celrep.2016.03.003

109. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med (2015) 66:17–29. doi: 10.1146/annurev-med-062613-093128

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Zhou and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.